MedTrace Logo

Terazosin And Metabolic Engagement in Alzheimer's Disease

NCT07796308 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-09-01

No results posted yet for this study

Summary

The TAME-AD trial will be a randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the metabolic target engagement of terazosin for the treatment of Alzheimer's disease.

Conditions

  • Alzheimer s Disease

Interventions

DRUG

Terazosin (Hytrin)

In this double blind, randomized, placebo controlled phase IIa clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 78 weeks. Participants will start at 1mg daily for the first 2 weeks, then the dosage will be increased to 5mg daily over 6 weeks, and continued through the end of the study.

OTHER

Placebo

In this double blind, randomized, placebo controlled phase IIa clinical trial, subjects randomized into the placebo group will receive placebo for 78 weeks.

Sponsors & Collaborators

  • Qiang Zhang

    lead OTHER

Principal Investigators

  • Qiang Zhang, MD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-08-01
Primary Completion
2031-07-31
Completion
2032-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07796308 on ClinicalTrials.gov